<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02162537</url>
  </required_header>
  <id_info>
    <org_study_id>METAL 2</org_study_id>
    <nct_id>NCT02162537</nct_id>
  </id_info>
  <brief_title>Therapeutic Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Brain Metastases</brief_title>
  <acronym>METAL2</acronym>
  <official_title>Multicentric, Randomized, Phase III Trial Comparing 2 Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Asymptomatic Brain Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Intercommunal Creteil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Groupe Francais De Pneumo-Cancerologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Intercommunal Creteil</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The patients carrying a complicated primary lung cancer brain metastases die in less than 3
      months of delay disease in the absence of treatment. The median survival of these patients is
      approximately six months when the treatment associated with radiotherapy chemotherapy based
      on cisplatin is now the standard treatment. In most studies the patients die of their brain
      disease in one case only two, so it is likely that some patients do not require brain
      irradiation (prognosis in this case is linked to extra-cerebral disease ). The benefits for
      patients in group B (without systematic irradiation) are not to suffer the side effects of
      this radiation. The risks are in the same group to see brain metastases become symptomatic.

      The role of cerebral radiotherapy in the patients treated with chemotherapy is unclear:
      should all patients be irradiated systematically (since the &quot;reference&quot; treatment is involved
      and with the aim of obtaining better control of the brain lesions and maintaining a better
      neurological status) or should only the patients showing cerebral progression be irradiated
      (avoidance of possibly useless brain radiotherapy and its side effects). The aim of this
      study is to better determine the position of cerebral radiotherapy in this context.

      Main objective:

      determine whether there is a difference in terms of progression-free survival between a
      therapeutic strategy with initial systematic brain radiotherapy followed by chemotherapy
      cis-platine/alimta + / - Bevacizumab and strategy with an initial chemotherapy
      cis-platine/alimta + / - Bevacizumab associated with brain radiotherapy only in cases of
      cerebral progression in patients with NSCLC with asymptomatic brain metastases
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a trial comparing two strategies with the aim to determine the best place for
      cerebral radiotherapy (initially or only systematic progression).

      Arm A: Initial cerebral radiotherapy and chemotherapy, standard arm Arm B: Chemotherapy and
      Radiotherapy brain if clinical or radiological cerebral progression , experimental arm (The
      chemotherapy treatments are standard treatments using drugs with authorization in this
      indication)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2013</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the progression-free survival rate in both arms</measure>
    <time_frame>From date of the randomization until the date of first detection of progression, or until the date of death, assessed up to up to approximately 90 months</time_frame>
    <description>Whether there is a difference in terms of progression-free survival between a therapeutic strategy with initial brain radiotherapy followed by systematic chemotherapy with cis-platinum / alimta and a strategy with initial chemotherapy with cis-platinum / alimta with brain radiotherapy only if brain progression in patients with non-small cell lung cancer with brain metastases asymptomatic.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From the date of randomization until the date of patient death, assessed up to 90 months</time_frame>
    <description>After 4 cycles of chemotherapy with platinum salt-pemetrexed (with or without bevacizumab) possibly followed, in case of control of the disease and if the patient's condition allows, by pemetrexed (alone or with bevacizumab if the latter was part of the initial treatment) as maintenance treatment until progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (response + stability)</measure>
    <time_frame>Baseline, between 21 and 28 days, then every 6 weeks, up to approximately 24 months</time_frame>
    <description>Repeat examinations to assess the measurable lesions or initials and examination necessary to confirm the appearance of a new lesion in case of clinical suspicion of disease progression (minimum CT scan and MRI).The radiological treatment response will be measured according to the RECIST 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>Every 3 weeks, up to approximately 24 months</time_frame>
    <description>The safety of the induction combination of cisplatin or carboplatin plus pemetrexed (Alimta®) +/- bevacizumab, the maintenance treatment with pemetrexed (Alimta®) +/- bevacizumab and the pancerebral radiotherapy will be assessed based on the CTC toxicity criteria v3.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment</measure>
    <time_frame>Baseline, between 21 and 28 days, then every 6 weeks, up to approximately 24 months</time_frame>
    <description>The quality of life assessment measurement will be performed by self-questionnaire. The EURO-QOL questionnaire will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological assessment</measure>
    <time_frame>Baseline, between 21 and 28 days, then every 6 weeks, up to approximately 24 months</time_frame>
    <description>The neurological assessment measurement will be performed by self-questionnaire. The MOCA questionnaires will be used.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Non-small Cell Lung Cancer Metastatic</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Adenocarcinoma of Lung Metastatic to Brain</condition>
  <condition>Cerebral Metastases</condition>
  <arm_group>
    <arm_group_label>Arm A (standard arm)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Arm A: Initial Cerebral Radiotherapy and Chemotherapy (Cisplatin and pemetrexed with or without Bevacizumab)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (experimental arm)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Arm B: Chemotherapy (Cisplatin and pemetrexed with or without Bevacizumab) and Cerebral Radiotherapy if clinical or radiological progression brain</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin 75 mg/m2 IV (with adequate hydration) on D1 every 3 weeks.</description>
    <arm_group_label>Arm A (standard arm)</arm_group_label>
    <arm_group_label>Arm B (experimental arm)</arm_group_label>
    <other_name>Cisplatine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>500mg/m² IV(10 min. infusion, preceded by the usual folic acid, vitamin B12 and corticosteroid premedication)on D1 every 3 weeks</description>
    <arm_group_label>Arm A (standard arm)</arm_group_label>
    <arm_group_label>Arm B (experimental arm)</arm_group_label>
    <other_name>Alimta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>7.5 mg/kg on D1 every 3 weeks. In case of eligibility for Bevacizumab, the latter will not be started until C2.</description>
    <arm_group_label>Arm A (standard arm)</arm_group_label>
    <arm_group_label>Arm B (experimental arm)</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Cerebral Radiotherapy</intervention_name>
    <description>Cerebral radiotherapy (encephalon in toto, 30 gy 10 sessions and 12 days) immediately after randomization before D1.If the number of brain metastases is less than or equal to 5 and less than or equal to 5 cm size, cerebral stereotactic radiotherapy condition may be proposed. The recommended interval between randomisation and D1 will be approximately 4 weeks.</description>
    <arm_group_label>Arm A (standard arm)</arm_group_label>
    <arm_group_label>Arm B (experimental arm)</arm_group_label>
    <other_name>Brain Radiotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with histologically or cytologically proven non-epidermoid, non-small cell
             lung cancer, non-EGFR (Epidermal Growth Factor Receptor)-mutated (or mutation test
             impracticable).

          2. Patients with brain metastasis/metastases without neurosurgical indication.

          3. Asymptomatic patients (without treatment or with stable steroids or antiepileptic
             treatments for ≥ 5 days prior to obtaining the baseline MRI of the brain, and ≥ 5 days
             prior to first dose of study treatment (Cycle 1, Day 1).

          4. At least one lesion measurable according to the RECIST (Response Evaluation Criteria
             in Solid Tumors) criteria.

          5. ECOG (Eastern Cooperative Oncology Group) Performance Status 0 - 1

          6. No previous chemotherapy for this cancer, apart from adjunctive chemotherapy more than
             18 months ago.

          7. Prior surgery is authorized in case of documented recurrence or progression.

          8. Adequate biological functions (hematologic, platelets, hemoglobin, hepatic function,
             alkaline phosphatases, ASAT (Aspartate transaminase) and ALAT (Alanine
             Aminotransferase); creatinine clearance).

          9. For women: Effective contraception for women of childbearing age during treatment and
             for 6 months following treatment.

             For men: They must be surgically sterile or accept the use of effective contraception
             until 6 months after the treatment period.

         10. Patients of more than 18 years of age.

         11. Estimated survival of at least 12 weeks.

         12. Consent signed by the patient

        Exclusion Criteria:

          1. Patients presenting with a brain lesion eligible for curative treatment
             (neurosurgical).

          2. Symptomatic brain metastasis/metastases in spite of symptomatic treatment.

          3. Epidermoid carcinoma.

          4. Con indication of Bevacizumab is furthermore

          5. Patients presenting with a brain lesion eligible for curative treatment (neurosurgery
             or radiosurgery).

          6. Symptomatic brain metastasis/metastases in spite of symptomatic treatment.

          7. Epidermoid carcinoma.

          8. Cons indication of Bevacizumab

          9. Inability to take the folic acid or vitamin B12 vitamin supplementation or the
             dexamethasone premedication (or any equivalent corticosteroid), or any inability to
             comply with the study procedures.

         10. History of cancer, with the exception of cervical cancer in situ, skin cancer other
             than melanoma, adequately treated low-grade prostatic cancer (Gleason score &lt;6),
             unless this cancer was diagnosed and treated more than 5 years ago without any signs
             of recurrence.

         11. Patients presenting with a systemic disorder which, in the investigator's opinion,
             compromises their participation in the study for reasons related to treatment safety
             or compliance.

         12. Patients incapable of discontinuing their aspirin treatment when the dose is &gt; 1300
             mg/day or their non-steroidal anti-inflammatory treatment two days before the day, on
             the day and two days the day of administration of pemetrexed (Alimta).

         13. Patients presenting with a 3rd sector (pleural effusion, ascites) which is clinically
             detectable and uncontrollable by simple measures of the evacuatory puncture type or
             other treatment before inclusion in the study.

         14. Patients presenting with neuropathy of grade &gt; 2 according to the criteria of CTC
             (Common toxicity Criteria) v3.0.

         15. Patients whose foreseeable compliance or geographical distance renders monitoring
             difficult.

         16. Pregnant or breast-feeding women.

         17. Significant weight loss (≥ 10%) during the 6 weeks preceding inclusion in the study.

         18. Vaccination against yellow fever within 30 days preceding inclusion in the study.

         19. Cons-indication to taking steroids

         20. Persons deprived of their liberty as a result of a judicial or administrative decision

         21. Concomitant participation in another trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabelle MONNET</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Intercommunal Créteil</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier du Pays d'Aix</name>
      <address>
        <city>Aix En Provence</city>
        <zip>13613</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques LE TREUT</last_name>
      <email>jletreut@ch-aix.fr</email>
    </contact>
    <investigator>
      <last_name>Jacques LE TREUT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Victor Dupouy</name>
      <address>
        <city>Argenteuil</city>
        <zip>95100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine RAYNAUD</last_name>
      <email>christine.raynaud@ch-argenteuil.fr</email>
    </contact>
    <investigator>
      <last_name>Christine RAYNAUD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre d'Oncologie et de Radiothérapie du Pays Basque</name>
      <address>
        <city>Bayonne</city>
        <zip>64100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurélien BLOUET</last_name>
      <email>aurelien.blouet@oncologie-pays-basque.org</email>
    </contact>
    <investigator>
      <last_name>Aurélien BLOUET</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Beauvais</city>
        <zip>60021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacky CREQUIT</last_name>
      <email>Jacky.crequit@orange.fr</email>
    </contact>
    <investigator>
      <last_name>Jacky CREQUIT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antoine CARPENTIER</last_name>
      <email>antoine.carpentier@avc.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Antoine CARPENTIER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HIA de Clermont-Tonnerre</name>
      <address>
        <city>Brest</city>
        <zip>22240</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas PALEIRON</last_name>
      <email>nicolas.paleiron@free.fr</email>
    </contact>
    <investigator>
      <last_name>Nicolas PALEIRON</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles ROBINET</last_name>
      <email>gilles.robinet@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Gilles ROBINET</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Radj GERVAIS</last_name>
      <email>r.gervais@baclesse.fr</email>
    </contact>
    <investigator>
      <last_name>Radj GERVAIS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Charleville Meziere</city>
        <zip>08000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphane CHOUABE</last_name>
      <email>Schouabe@ch-charleville-mezieres.fr</email>
    </contact>
    <investigator>
      <last_name>Stéphane CHOUABE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Laennec</name>
      <address>
        <city>Creil</city>
        <zip>60109</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandrine LOUTSKI-VETTESE</last_name>
      <email>sandrine.loutski@ch-creil.fr.fr</email>
    </contact>
    <investigator>
      <last_name>Sandrine LOUTSKI-VETTESE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle MONNET</last_name>
      <email>isabelle.monnet@chicreteil.fr</email>
    </contact>
    <investigator>
      <last_name>Isabelle MONNET</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Draguignan</city>
        <zip>83300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hervé LE CAER</last_name>
      <email>herve.lecaer@ch-draguignan.fr</email>
    </contact>
    <investigator>
      <last_name>Hervé LE CAER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>GAP</city>
        <zip>05000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal THOMAS</last_name>
      <email>pascal.thomas@chicas-gap.fr</email>
    </contact>
    <investigator>
      <last_name>Pascal THOMAS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Robert Boulin</name>
      <address>
        <city>Libourne</city>
        <zip>33500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samir ABDICHE</last_name>
      <email>samir.abdiche@ch-libourne.fr</email>
    </contact>
    <investigator>
      <last_name>Samir ABDICHE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Le Cluzeau</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain VERGNENEGRE</last_name>
      <email>avergne@unilim.fr</email>
    </contact>
    <investigator>
      <last_name>Alain VERGNENEGRE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional</name>
      <address>
        <city>Longjumeau</city>
        <zip>91161</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gérard OLIVIERO</last_name>
      <email>gerard.oliviero@ch-longjumeau.fr</email>
    </contact>
    <investigator>
      <last_name>Gérard OLIVIERO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Bretagne Sud</name>
      <address>
        <city>Lorient</city>
        <zip>56322</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Régine LAMY</last_name>
      <email>r.lamy@ch-bretagne-sud.fr</email>
    </contact>
    <investigator>
      <last_name>Régine LAMY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maurice PEROL</last_name>
      <email>maurice.perol@lyon.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Maurice PEROL</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Les Chanaux</name>
      <address>
        <city>Macon</city>
        <zip>71000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique ARPIN</last_name>
      <email>doarpin@ch-macon.fr</email>
    </contact>
    <investigator>
      <last_name>Dominique ARPIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier F. QUESNAY</name>
      <address>
        <city>Mantes La Jolie</city>
        <zip>78200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Bernard AULIAC</last_name>
      <email>j-b.auliac@ch-mantes-la-jolie.rss.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Bernard AULIAC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmette</name>
      <address>
        <city>Marseille</city>
        <zip>13000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne MADROSZYC</last_name>
      <email>madroszyca@marseille.fnclcc.fr</email>
    </contact>
    <investigator>
      <last_name>Anne MADROSZYC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord APHM</name>
      <address>
        <city>Marseille</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent GREILLIER</last_name>
      <email>laurent.greillier@mail.ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Laurent GREILLIER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Meaux</city>
        <zip>77108</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chrystèle LOCHER</last_name>
      <email>ch-locher@ch-meaux.fr</email>
    </contact>
    <investigator>
      <last_name>Chrystèle LOCHER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal</name>
      <address>
        <city>Meulan</city>
        <zip>78250</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Etienne LEROY-TERQUEM</last_name>
      <email>etiennelt@hotmail.fr</email>
    </contact>
    <investigator>
      <last_name>Etienne LEROY-TERQUEM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique du Pont de Chaume</name>
      <address>
        <city>Montauban</city>
        <zip>82000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franck THOUVENY</last_name>
      <email>fthouveny@clinique-pontdechaume.fr</email>
    </contact>
    <investigator>
      <last_name>Franck THOUVENY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Perigueux</city>
        <zip>24019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Yves DELHOUME</last_name>
      <email>jy.delhoume@ch-perigeux.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Yves DELHOUME</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Catalan d'Oncologie</name>
      <address>
        <city>Perpignan</city>
        <zip>66000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine VIEILLOT</last_name>
      <email>sabinevieillot@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Sabine VIEILLOT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier René Dubos</name>
      <address>
        <city>Pontoise</city>
        <zip>95303</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gislaine FRABOULET</last_name>
      <email>gislaine.fraboulet@ch-pontoise.fr</email>
    </contact>
    <investigator>
      <last_name>Gislaine FRABOULET</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de la Région d'Annecy (CHRA)</name>
      <address>
        <city>Pringy</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chantal DECROISETTE</last_name>
      <email>cdecroisette@ch-annecy.fr</email>
    </contact>
    <investigator>
      <last_name>Chantal DECROISETTE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal de Cornouaille</name>
      <address>
        <city>Quimper</city>
        <zip>29107</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Marie CHIAPPA</last_name>
      <email>am.chiappa@ch-cornouaille.fr</email>
    </contact>
    <investigator>
      <last_name>CHIAPPA Anne-Marie</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Pontchailloux</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hervé LENA</last_name>
      <email>herve.lena@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Hervé LENA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>79031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzanna BOTA</last_name>
      <email>Suzanna.bota@chu-rouen.fr</email>
    </contact>
    <investigator>
      <last_name>Suzanna BOTA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Mutualiste de l'Estuaire</name>
      <address>
        <city>Saint Nazaire</city>
        <zip>44600</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe DEGUIRAL</last_name>
      <email>philippe.deguiral@mla.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe DEGUIRAL</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de la Loire (I.C.L)</name>
      <address>
        <city>Saint Priest En Jarez</city>
        <zip>42271</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre FOURNEL</last_name>
      <email>pierre.fournel@icloire.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre FOURNEL</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Salon de Provence</name>
      <address>
        <city>Salon de Provence</city>
        <zip>13658</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques LE TREUT</last_name>
      <email>jletreut@ch-aix.fr</email>
    </contact>
    <investigator>
      <last_name>Jacques LE TREUT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Sens</city>
        <zip>89108</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GONZALEZ Gilles</last_name>
      <email>ggonzalez@ch-sens.fr</email>
    </contact>
    <investigator>
      <last_name>GONZALEZ Gilles</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roland SCHOTT</last_name>
      <email>rschott@strasbourg.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Roland SCHOTT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital d'Instruction des Armées Sainte Anne</name>
      <address>
        <city>Toulon</city>
        <zip>83800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henri BERARD</last_name>
      <email>hberard@libertysurf.fr</email>
    </contact>
    <investigator>
      <last_name>Henri BERARD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Larrey</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence BIGAY-GAME</last_name>
      <email>bigaygame.l@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Laurence BIGAY-GAME</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier GALLOCHER</last_name>
      <email>o.gallocher@clinique-pasteur.com</email>
    </contact>
    <investigator>
      <last_name>Olivier GALLOCHER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Villefranche Sur Saone</city>
        <zip>69655</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lionel FALCHERO</last_name>
      <email>lfalchero@ch-villefranche.fr</email>
    </contact>
    <investigator>
      <last_name>Lionel FALCHERO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2014</study_first_submitted>
  <study_first_submitted_qc>June 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2014</study_first_posted>
  <last_update_submitted>July 31, 2017</last_update_submitted>
  <last_update_submitted_qc>July 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Intercommunal Creteil</investigator_affiliation>
    <investigator_full_name>Isabelle MONNET</investigator_full_name>
    <investigator_title>Physician</investigator_title>
  </responsible_party>
  <keyword>Strategy</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Cisplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

